New hope for HIV patients running out of treatment options
NCT ID NCT03902522
Summary
This study tested an experimental drug called PRO 140, given as a shot, in combination with other HIV medications. It was for adults whose current HIV drugs were no longer working well due to the virus becoming resistant. The main goal was to see if this new combination could safely lower the amount of virus in the blood and improve the body's immune defenses over 25 weeks.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV-1-INFECTION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CD02_OpenLabel Investigational Site
Palm Springs, California, 92262, United States
-
CD02_OpenLabel Investigational Site
San Francisco, California, 94115, United States
-
CD02_OpenLabel Investigational Site
New Haven, Connecticut, 06510, United States
-
CD02_OpenLabel Investigational Site
Ft. Pierce, Florida, 34982, United States
-
CD02_OpenLabel Investigational Site
Miami, Florida, 33136, United States
-
CD02_OpenLabel Investigational Site
Miami, Florida, 33139, United States
-
CD02_OpenLabel Investigational Site
Miami, Florida, 33169, United States
-
CD02_OpenLabel Investigational Site
Orlando, Florida, 32803, United States
-
CD02_OpenLabel Investigational Site
West Palm Beach, Florida, 33401, United States
-
CD02_OpenLabel Investigational Site
Decatur, Georgia, 30033, United States
-
CD02_OpenLabel Investigational Site
Chicago, Illinois, 60613, United States
-
CD02_OpenLabel Investigational Site
Wichita, Kansas, 67214, United States
-
CD02_OpenLabel Investigational Site
Syracuse, New York, 13210, United States
-
CD02_OpenLabel Investigational Site
Bellaire, Texas, 77301, United States
-
CD02_OpenLabel Investigational Site
Houston, Texas, 77004, United States
-
CD02_OpenLabel Investigational Site
Houston, Texas, 77098, United States
-
CD02_OpenLabel Investigational Site
Spokane, Washington, 99202, United States
Conditions
Explore the condition pages connected to this study.